Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Anticipated CAGR of the Pharmacogenomics Market, and What Factors Will Drive It?

There has been a swift expansion in the pharmacogenomics market size in the latter years. The expectation is for an upturn from $8.94 billion in 2024 to $9.84 billion in 2025, showing a compound annual growth rate (CAGR) of 10.0%. The notable growth during the historic span is due to the robust economic development in burgeoning markets, a heightened emphasis on bespoke medicine, the escalation in advanced healthcare structures, and elevated healthcare spending.

Expectations are high for a swift surge in the pharmacogenomics market in the coming years, with forecasts predicting the size to escalate to $14.53 billion by 2029, marking a compound annual growth rate (CAGR) of 10.2%. This projected increase during the forecast period is largely linked to an aging population, the prevalence of chronic diseases, population growth, and the heightened demand for cancer treatments. Key trends to watch for during this period include the introduction of genome editing solutions for advanced therapy analysis, the incorporation of artificial intelligence (AI) into genomics for enhanced genetic data examination, progress in metagenomics, strategic alliances and collaborations within the market, the utilization of three-dimensional (3D) genomics to investigate gene expression and function influences, novel product innovations targeting infectious diseases and gene editing, and the creation of psychotropic pharmacogenomics tests for insightful decision-making.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7072&type=smp

What Are the Core Growth Drivers Propelling the Pharmacogenomics Market Forward?

The pharmacogenomics market is experiencing increasing demand, largely fueled by the growing need for precision medicine. This medical model is focused on providing tailored healthcare, meaning that treatments, practices, and products are specifically adapted to the needs of individual patients, rather than a generic one-size-fits-all approach. Oncology is currently the field making the most use of precision medicine, but its potential reaches far beyond; it can also be applied to late-stage diseases, including rare and genetic diseases. The intent of precision medicine is to use information about specific diseases and their reactions to particular treatments in a more personalized, effective way. A March 2022 article on Linchpinseo suggested a 1/3 increase in precision medicine investment from major pharmaceutical companies over the next five years. In addition, there are 30 million individuals diagnosed and treated for type 2 diabetes in the USA, for whom precision medicine could greatly enhance treatment practices. Therefore, the surging demand for precision medicine is expected to positively impact the pharmacogenomics market.

What Segment Types Define the Pharmacogenomics Market Structure?

The pharmacogenomicsmarket covered in this report is segmented –

1) By Technology: Next Generation Sequencing, Polymerase Chain Reaction, Gel Electrophoresis, Mass Spectrometry, Microarray, Other Technologies

2) By Application: Neurological Diseases, Infectious Diseases, Oncology, Cardiovascular Diseases, Pain Management, Other Applications

3) By End User: Hospitals and Clinics, Research Institutions, Academic Institutes, Other End Users

Subsegments:

1) By Next Generation Sequencing (NGS): Whole Genome Sequencing, Targeted Sequencing, Exome Sequencing

2) By Polymerase Chain Reaction (PCR): Quantitative PCR (qPCR), Reverse Transcription PCR (RT-PCR), Digital PCR

3) By Gel Electrophoresis: Agarose Gel Electrophoresis, Polyacrylamide Gel Electrophoresis, Capillary Gel Electrophoresis

4) By Mass Spectrometry: LC-MS/MS (Liquid Chromatography-Tandem Mass Spectrometry), MALDI-TOF MS (Matrix-Assisted Laser Desorption/Ionization Time of Flight), HRMS (High-Resolution Mass Spectrometry)

5) By Microarray: SNP Microarrays, Expression Microarrays, Comparative Genomic Hybridization (CGH) Arrays

6) By Other Technologies: Sanger Sequencing, CRISPR-Based Technologies, Bioinformatics Tools

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7072&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Pharmacogenomics Market?

North America was the largest region in the pharmacogenomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacogenomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Emerging Trends that Are Influencing thePharmacogenomics Industry Evolution?

The rise in technological innovation is a major trend gaining traction in the pharmacogenomics industry. Pharmaceutical manufacturers are honing various strategies for pharmacogenomics analysis in order to deliver cost-effective screening solutions for identified polymorphisms and the identification of new variants. To illustrate, Invitae, a medical laboratory based in the US, unveiled its improved Pharmacogenomics Panel in May 2022. The expanded Invitae Pharmacogenomics (PGx) Panel, which includes the Mental Health Panel, offers insights into how genes interact with medicine in different specialties such as primary care, cardiology, and oncology. Considering that around 25% of patients experience unique drug responses due to genetic factors, the use of PGx testing is poised to become a common practice. However, effective incorporation into healthcare mandates increased support for providers to comprehend and utilize PGx testing in their clinical environments.

View the full report here:

https://www.thebusinessresearchcompany.com/report/pharmacogenomics-global-market-report

What Is the Definition of the Pharmacogenomics Market?

Pharmacogenomics is a field of research that studies how a patient’s genes affect and how they respond to medications. The long-term aim of pharmacogenomics is to help doctors select the drugs and doses best suited for each person. Pharmacogenomics is used to create customized drugs to treat a variety of health issues, including cardiovascular disease, Alzheimer’s disease, cancer, and asthma. The pharmacogenomics marker refers to precise medical treatment for each person or a group of people.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7072

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model